Immunological and Autoimmune Disorders

FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead candidate developed using its trademark Cymerus’s mesenchymal stem cell (MSC), which in turn are derived from allogeneic induced pluripotent stem cells (iPSCs) based drug production platform. Graft-versus-host disease is an immune condition that occurs in a patient after transplantation when immune cells present in donor tissue (the graft) attack the host's ...